Business · India Bureau
Cancer Drug Price Caps Leave Quarter of Medicines Unchanged
New Delhi's move to regulate trade margins on non-scheduled anti-cancer drugs has reduced prices for most medications, but an analysis reveals nearly 25 percent of listed medicine packs saw no price adjustment, raising concerns about the measure's effectiveness.
LSN India ·
A review of National Pharmaceutical Pricing Authority data has exposed significant limitations in the Centre's recent intervention to control cancer drug costs. While the government's decision to cap trade margins on 137 non-scheduled anti-cancer drugs resulted in maximum retail price reductions for 484 of 643 listed medicine packs, the analysis found that 159 packs—approximately one in four—remained at unchanged price points.
The pricing intervention was intended to ease the financial burden on cancer patients by making treatments more affordable. However, the inability to reduce prices across the entire portfolio of medications suggests the policy may deliver only partial relief to those seeking these critical drugs.
Experts point to the complexity of pharmaceutical pricing mechanisms as a contributing factor to the uneven outcomes. The unchanged prices may reflect cases where existing rates already aligned with the new trade margin caps, or where competing market dynamics had already influenced pricing decisions prior to the government's action.
The findings raise questions about the effectiveness of margin-capping as a standalone strategy for controlling drug costs in India's oncology sector. Health advocates have called for a comprehensive assessment of the policy's impact and potential refinements to ensure maximum benefit for cancer patients across all therapeutic categories and dosage combinations.